Celcuity Inc. (CELC) Stock: Promising Phase 3 Breast Cancer Data Fuels Growth Hopes

TLDR CELC stock fell 0.49% to $65.25, then dipped another 1.39% after hours to $64.34. Gedatolisib triplet delivers 21.5 months without progression in one key subgroup. Triplet response rate reaches 59%, versus 33% for the control treatment group. Gedatolisib dropout rates hit 5% and 4%, versus 19% for alpelisib treatment. Eight-study analysis favors gedatolisib regimens [...]

The post Celcuity Inc. (CELC) Stock: Promising Phase 3 Breast Cancer Data Fuels Growth Hopes appeared first on Blockonomi.